20
Participants
Start Date
April 4, 2018
Primary Completion Date
March 10, 2020
Study Completion Date
March 10, 2020
CAP-1002
The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic, anti-inflammatory, and pro-angiogenic.
Placebo
Placebo
Nemours Children's Hospital, Orlando
Cincinnati Children's Hospital Medical Center, Cincinnati
University of Iowa, Iowa City
Children's Hospital Wisconsin, Milwaukee
Washington University, St Louis
Children's Hospital Colorado, Aurora
University of Utah, Salt Lake City
University of California, Davis, Sacramento
University of Massachusetts Medical Center, Worcester
Capricor Inc.
INDUSTRY